Leerink Partnrs Comments on Kura Oncology Q2 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Kura Oncology in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of $0.14 per share for the quarter. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q3 2025 earnings at ($0.08) EPS and Q4 2025 earnings at ($0.06) EPS.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period last year, the firm earned ($0.50) earnings per share.

A number of other research firms have also recently commented on KURA. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Jefferies Financial Group lowered their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Finally, StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Price Performance

Kura Oncology stock opened at $8.65 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17. The stock has a market capitalization of $672.62 million, a P/E ratio of -3.67 and a beta of 0.78. The stock has a fifty day moving average of $8.79 and a 200-day moving average of $15.11.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,255 shares of company stock worth $100,739. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently made changes to their positions in KURA. nVerses Capital LLC bought a new stake in shares of Kura Oncology during the 3rd quarter valued at about $25,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology during the 4th quarter valued at about $90,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after purchasing an additional 1,750 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Kura Oncology during the 3rd quarter valued at about $146,000. Finally, AlphaQuest LLC bought a new stake in shares of Kura Oncology during the 4th quarter valued at about $177,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.